These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20103606)

  • 1. Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro.
    Muzza M; Cordella D; Bombled J; Bressac-de Paillerets B; Guizzardi F; Francis Z; Beck-Peccoz P; Schlumberger M; Persani L; Fugazzola L
    Eur J Endocrinol; 2010 Apr; 162(4):771-7. PubMed ID: 20103606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.
    Prazeres H; Couto JP; Rodrigues F; Vinagre J; Torres J; Trovisco V; Martins TC; Sobrinho-Simões M; Soares P
    Endocr Relat Cancer; 2011 Aug; 18(4):401-12. PubMed ID: 21551259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma.
    Cordella D; Muzza M; Alberti L; Colombo P; Travaglini P; Beck-Peccoz P; Fugazzola L; Persani L
    Endocr Relat Cancer; 2006 Sep; 13(3):945-53. PubMed ID: 16954442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medullary Thyroid Carcinoma Associated with Germline RET
    Xu JY; Grubbs EG; Waguespack SG; Jimenez C; Gagel RF; Sosa JA; Sellin RV; Dadu R; Hu MI; Trotter CS; Jackson M; Rich TA; Hyde SM; Sherman SI; Cote GJ
    Thyroid; 2016 Dec; 26(12):1744-1751. PubMed ID: 27673361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.
    Cosci B; Vivaldi A; Romei C; Gemignani F; Landi S; Ciampi R; Tacito A; Molinaro E; Agate L; Bottici V; Cappagli V; Viola D; Piaggi P; Vitti P; Pinchera A; Elisei R
    Endocr Relat Cancer; 2011 Oct; 18(5):603-12. PubMed ID: 21810974
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Qi XP; Jin BY; Li PF; Wang S; Zhao YH; Cao ZL; Yu XH; Cheng J; Fang XD; Zhao JQ
    Thyroid; 2019 Oct; 29(10):1447-1456. PubMed ID: 31364476
    [No Abstract]   [Full Text] [Related]  

  • 7. Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism.
    Borrello MG; Aiello A; Peissel B; Rizzetti MG; Mondellini P; Degl'Innocenti D; Catalano V; Gobbo M; Collini P; Bongarzone I; Pierotti MA; Greco A; Seregni E
    Endocr Relat Cancer; 2011 Aug; 18(4):519-27. PubMed ID: 21690267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series.
    Fugazzola L; Muzza M; Mian C; Cordella D; Barollo S; Alberti L; Cirello V; Dazzi D; Girelli ME; Opocher G; Beck-Peccoz P; Persani L
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):418-25. PubMed ID: 18284634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma.
    Silva AL; Carmo F; Moura MM; Domingues R; Espadinha C; Leite V; Cavaco B; Bugalho MJ
    Endocrine; 2015 Jun; 49(2):366-72. PubMed ID: 25725622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies.
    Colombo C; Minna E; Rizzetti MG; Romeo P; Lecis D; Persani L; Mondellini P; Pierotti MA; Greco A; Fugazzola L; Borrello MG
    Orphanet J Rare Dis; 2015 Mar; 10():25. PubMed ID: 25887804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases.
    Hedayati M; Nabipour I; Rezaei-Ghaleh N; Azizi F
    Med J Malaysia; 2006 Dec; 61(5):564-9. PubMed ID: 17623957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Y606C RET mutation causes a receptor gain of function.
    Ercolino T; Lombardi A; Becherini L; Piscitelli E; Cantini G; Gaglianò MS; Serio M; Luconi M; Mannelli M
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):253-8. PubMed ID: 18248647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of inherited genetic variants in ret proto-oncogene of Brazilian patients with apparently sporadic medullary thyroid carcinoma.
    Guerrero IM; Pessoa CH; Olmedo DB; Pontes ER; Matos LC; Tilli TM; Barcinski MA; Gimba ER
    Thyroid; 2006 Jan; 16(1):9-15. PubMed ID: 16487008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma.
    Colombo-Benkmann M; Li Z; Riemann B; Hengst K; Herbst H; Keuser R; Gross U; Rondot S; Raue F; Senninger N; Pützer BM; Frank-Raue K
    Eur J Endocrinol; 2008 Jun; 158(6):811-6. PubMed ID: 18322301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece.
    Sarika HL; Papathoma A; Garofalaki M; Vasileiou V; Vlassopoulou B; Anastasiou E; Alevizaki M
    Clin Endocrinol (Oxf); 2012 Dec; 77(6):857-62. PubMed ID: 22676047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 6-Base Pair in Frame Germline Deletion in Exon 7 Of RET Leads to Increased RET Phosphorylation, ERK Activation, and MEN2A.
    Latteyer S; Klein-Hitpass L; Khandanpour C; Zwanziger D; Poeppel TD; Schmid KW; Führer D; Moeller LC
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1016-22. PubMed ID: 26765577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma.
    Fazioli F; Piccinini G; Appolloni G; Bacchiocchi R; Palmonella G; Recchioni R; Pierpaoli E; Silvetti F; Scarpelli M; Bruglia M; Melillo RM; Santoro M; Boscaro M; Taccaliti A
    Thyroid; 2008 Jul; 18(7):775-82. PubMed ID: 18631007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.